Skip to content

LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs

  • A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1.
  • She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation

Ballerup, Denmark, June 2, 2025 – LEO Pharma, a leader in medical dermatology focused on innovative solutions for skin health, today announces the appointment of Helle Hedegaard Juhl as EVP for Global People & Corporate Affairs (GPCA). Helle will join the Global Leadership Team to lead LEO Pharma's people strategy to support its transformation and assist in developing the organization. Her appointment, alongside EVP International Operations, Frederik Kier further strengthens the company’s strategy to lead the field of medical dermatology.

 

Helle comes with more than 20 years of experience in a variety of HR roles within the pharmaceutical industry. After nearly 6 years as Chief Human Resources Officer at Esteve, an international specialty pharmaceutical company, headquartered in Spain, Helle will join LEO Pharma’s Global Leadership Team and head up Global People & Corporate Affairs. 

 

I am really looking forward to being part of the LEO Pharma team and to meeting colleagues from across the organization as soon as possible. I’m excited to contribute to the next stage of LEO Pharma’s transformation journey as we partner to shape the future of dermatology,” says Helle Hedegaard Juhl .

 

Prior to joining the Esteve executive leadership team, Helle spent 16 years at Lundbeck, a Danish-headquartered pharmaceutical company, in various roles within the HR organization, including Global HR Manager and HR Senior Director.

 

Helle has a highly experienced profile and will support our quest for becoming the global leader in medical dermatology through the people-lens, strengthening the capabilities of the HR team while focusing on shaping our unique culture, ” says CEO, Christophe Bourdon

 

The announcement of a new EVP for GPCA is part of broader leadership changes revealed in mid-May to support LEO Pharma's long-term strategy and transformation. The Product Strategy and International Operations function was split, with a new EVP for International Operations starting in June 2025 and an interim leader appointed for Global Product Strategy while the search for a permanent head is underway. At the same time, an interim EVP for Development has been appointed during the search for a permanent replacement, aiming to unlock the full potential of our strategic portfolio through global launches and expanded indications.

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com

MEDIA INQUIRIES
Jeppe Ilkjaer

Jeppe Ilkjaer

Head of Media
Tel: +45 30502014